
Oncology Pipeline
Research & Development
Our Pipeline
At Servier Pharmaceuticals, we are committed to building a robust portfolio of treatments starting with oncology and potentially expanding to other therapeutic areas. Advancing innovation for patients is at the heart of everything we do. Globally, we are continuously reinvesting 25 percent of our revenue (excluding generics) in our own research or through alliances and partnerships that drive research and development to address unmet patient needs in various therapeutic areas.
Our global pipeline includes more than a dozen oncology projects at varying stages of clinical development.
Hematological Malignancies
Molecule Area | Primary Indication | Partner | Territory | Phase |
---|
Solid Tumors
Molecule Area | Primary Indication | Partner | Territory | Phase |
---|
More from Servier
Research & Development
We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.
Learn MoreClinical Trials
We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.
Learn MoreAbout Us
Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.
Learn More